Latest revenue
$2.4M
as of 2025-12-31
Latest net income
$-34.8M
as of 2025-12-31
Net margin
-1462.8%
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ATOS is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $38.3M
- Enterprise value
- $6.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 1.26×
- Dividend yield
- 0.0%
- 52-wk high
- $7.56
- 52-wk low
- $0.53
- Beta
- —
- Shares out
- 8.6M
5-year trend
What this company does
ITEM 1. BUSINESS Overview We are a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology, with a focus on breast cancer and other breast conditions. Our lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator (SERM)/ selective estrogen receptor degrader (SERM/D) currently in Phase 2 clinical development. The Company is evaluating potential indications for (Z)-endoxifen based on its pharmacologic profile, including its potential for both reducing the risk of and for the treatment of breast cancer, as well as in other therapeutic areas. We have been granted U.S. and international…
AI summary unavailable — showing raw filing excerpt
Generated from ATOS's filing dated 2026-03-25
Key risks
ITEM 1A. RISK FACTORS Summary of Risk Factors Our business is subject to a number of risks and uncertainties, including risks and uncertainties that may prevent us from achieving our business objectives or may adversely affect our business, clinical and commercialization activities, the manufacturing of our product candidates, intellectual property, third party relationships, competitive environment, product and environmental liabilities, our ability to continue as a going concern and our common stock. Purchasing shares of common stock is an investment in our securities and involves a high degree of risk and uncertainty. You should carefully consider the following information about these…
AI summary unavailable — showing raw filing excerpt
Generated from ATOS's filing dated 2026-03-25
Profitability
Operating margin
-1562.5%
129.1%Net margin
-1462.8%
132.3%Return on equity
-48.6%
36.3%Return on assets
-73.0%
118.9%Leverage
Debt / equity
-0.33×
580.6%Debt / assets
-50.1%
871.6%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-9.6M | -42.7% | — |
Q4 2025 2025-12-31 | — | — | $-10.9M | -72.3% | — |
Q3 2025 2025-09-30 | — | — | $-8.7M | -20.2% | — |
Q2 2025 2025-06-30 | — | — | $-8.4M | -39.2% | — |
Q1 2025 2025-03-31 | — | — | $-6.7M | -14.3% | — |
Q4 2024 2024-12-31 | — | — | $-6.3M | — | — |
Q3 2024 2024-09-30 | — | — | $-7.2M | -16.1% | — |
Q2 2024 2024-06-30 | — | — | $-6.0M | +38.5% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ATOS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ATOS
Institutional value
$3.3M
Total shares held
631.7K
Distinct holders
17
-49 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 349.1K | $1.8M | — | New |
| 2 | BlackRock, Inc. | 133.2K | $700.5K | -1.9M (-93.3%) | Trimmed |
| 3 | UBS Group AG | 92.0K | $484.1K | -298.0K (-76.4%) | Trimmed |
| 4 | VANGUARD FIDUCIARY TRUST CO | 52.2K | $274.8K | — | New |
| 5 | Vanguard Global Advisers, LLC | 3.1K | $16.2K | — | New |
| 6 | GROUP ONE TRADING LLC | 609 | $3.2K | -6.1K (-90.9%) | Trimmed |
| 7 | JPMORGAN CHASE & CO | 383 | $1.8K | -37.7K (-99.0%) | Trimmed |
| 8 | WELLS FARGO & COMPANY/MN | 296 | $1.6K | +213 (+256.6%) | Added |
| 9 | SBI Securities Co., Ltd. | 113 | $594 | -1.5K (-92.8%) | Trimmed |
| 10 | TD Waterhouse Canada Inc. | 103 | $525 | -1.5K (-93.4%) | Trimmed |
| 11 | BNP PARIBAS FINANCIAL MARKETS | 98 | $515 | -1.4K (-93.5%) | Trimmed |
| 12 | North Star Investment Management Corp. | 80 | $421 | — | New |
| 13 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 46 | $242 | -454 (-90.8%) | Trimmed |
| 14 | Napier Financial, LLC | 6 | $32 | — | New |
| 15 | Bogart Wealth, LLC | 5 | $26 | — | New |
| 16 | Clearstead Advisors, LLC | 4 | $22 | -66 (-94.3%) | Trimmed |
| 17 | Avion Wealth | 318 | $1 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ATOS's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.